Trial Profile
A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Mavodelpar (Primary)
- Indications Metabolic disorders
- Focus Adverse reactions
- Sponsors High Point Pharmaceuticals
- 09 Aug 2022 According to Reneo Pharmaceuticals media release, the study published in the Journal of Clinical Trials.
- 30 Jun 2022 According to Reneo Pharmaceuticals media release, data from this study has been accepted for presentation at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
- 08 Apr 2015 New trial record